CDK

Cat. No.

A54342

CAS No.

2764866-21-7

Cdc7-IN-14

Cdc7-IN-14 is a highly potent inhibitor of CDC7, exhibiting an IC50 of less than 1 nM. This compound demonstrates significant efficacy in disrupting the regulation of cell cycle progression, making it a valuable tool for cancer research. Its ability to inhibit CDC7 offers insights into the underlying mechanisms of tumor cell proliferation and underscores its potential in therapeutic applications.

Cat. No.

A54344

CAS No.

2764866-23-9

Cdc7-IN-13

Cdc7-IN-13 is a potent inhibitor of CDC7 with an IC50 of less than 1 nM, demonstrating significant enzymatic activity inhibition. This compound is primarily utilized in cancer research to investigate the role of CDC7 in cell cycle regulation and its implications in tumorigenesis. Cdc7-IN-13 offers a valuable tool for exploring therapeutic strategies targeting cell division in various malignant cell lines.

Cat. No.

A54345

CAS No.

388626-12-8

TrkA Inhibitor

TrkA Inhibitor is a selective CDK2 inhibitor, demonstrating an IC50 of 0.69 μM against CDK1. This compound is particularly valuable in research focused on chemotherapy-induced alopecia, allowing for the investigation of mechanisms involved in hair follicle cycling and potential therapeutic interventions. Its specificity for CDK2 makes it a useful tool in examining cell cycle regulation and associated pathways in various biological contexts.

Cat. No.

A54346

CAS No.

2479306-60-8

CDK9-IN-19

CDK9-IN-19 is a selective inhibitor of Cyclin-Dependent Kinase 9 (CDK9), exhibiting a potent IC50 value of 2.0 nM. This compound demonstrates significant antiproliferative activity in cellular assays and effectively suppresses tumor growth in MV4-11 xenograft models. With moderate pharmacokinetic properties and minimal hERG inhibition, CDK9-IN-19 is valuable for research on acute myeloid leukemia (AML) and related oncogenic pathways.

Cat. No.

A54347

CAS No.

2872677-61-5

CDK9-IN-22

CDK9-IN-22 is a selective inhibitor of cyclin-dependent kinase 9 (CDK9) with an IC50 of 10.4 nM for CDK9, demonstrating significant efficacy in disrupting cellular pathways. This compound is known to induce apoptosis and promote cell cycle arrest at the G2/M phase. Additionally, CDK9-IN-22 decreases the levels of phosphorylated RNA polymerase II (S2) and CDK9 protein, exhibiting notable antiproliferative and anti-tumor properties. It is a valuable tool for research in cancer biology and therapeutic applications targeting CDK9-related pathways.

Cat. No.

A54348

CAS No.

7403-44-3

P18IN005 hydrochloride

P18IN005 hydrochloride is a selective inhibitor of cyclin-dependent kinase (CDK), primarily targeting p18. This compound effectively regulates hematopoietic stem cell (HSC) self-renewal, demonstrating superior potency compared to p27 in mouse models. P18IN005 hydrochloride enhances the expansion of functional HSCs in short-term cultures, making it a valuable reagent for investigating the signaling pathways that govern stem cell self-renewal and differentiation processes.

Cat. No.

A54349

CAS No.

2253686-94-9

Cdc7-IN-17

Cdc7-IN-17 is a potent inhibitor of CDC7, exhibiting an IC50 of less than 10 μM. This compound is designed for use in cancer research, particularly in studies focusing on cell cycle regulation and tumor progression. By targeting CDC7, Cdc7-IN-17 offers valuable insights into the mechanisms of cancer proliferation and potential therapeutic strategies.

Cat. No.

A54350

CAS No.

2699091-15-9

CDK4/6-IN-14

CDK4/6-IN-14 is a potent and highly selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), displaying IC50 values of 10 nM and 16 nM, respectively. This compound exhibits over 60-fold selectivity compared to CDK1, CDK2, CDK7, and CDK9, while demonstrating high specificity against a broader panel of 205 kinases. CDK4/6-IN-14 is valuable for research into cell cycle regulation and has potential applications in studying cancer therapeutics and targeted therapies.

Cat. No.

A54352

CAS No.

852678-17-2

CDK9-IN-15

CDK9-IN-15 is a selective inhibitor of cyclin-dependent kinase 9 (CDK9), a key regulator of transcription elongation. By inhibiting CDK9, this compound effectively reduces the phosphorylation of RNA polymerase II, leading to decreased transcriptional activity of oncogenes. CDK9-IN-15 is primarily utilized in cancer research to explore therapeutic strategies that target transcriptional regulation in malignancies.

Cat. No.

A54353

CAS No.

2765676-20-6

CDK7-IN-13

CDK7-IN-13 is a potent inhibitor of cyclin-dependent kinase 7 (CDK7), with a pyrimidinyl derivative structure. This compound exhibits significant activity against cancer cells characterized by transcriptional dysregulation, making it a valuable tool for cancer research. Its application in studies targeting CDK7 may enhance the understanding of cancer biology and aid in the development of novel therapeutic strategies.

Cat. No.

A54355

CAS No.

2987897-20-9

CDK9-IN-48

CDK9-IN-48 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9), demonstrating an IC50 value of 1.37 nM. This compound effectively suppresses the proliferation of a variety of cancer cell lines, making it a valuable tool in cancer research. CDK9-IN-48 is particularly relevant for studies focused on acute myeloid leukemia and prostate cancer, where targeting CDK9 may provide therapeutic benefits.

Cat. No.

A54356

CAS No.

2407774-31-4

CDK12/13-IN-1

CDK12/13-IN-1 is a selective inhibitor of cyclin-dependent kinases 12 and 13 (CDK12/13). This compound demonstrates significant antitumor activity by interfering with the phosphorylation of RNA polymerase II, thereby disrupting transcriptional regulation in cancer cells. CDK12/13-IN-1 is utilized in research focused on cancer biology, particularly in exploring therapeutic strategies for tumors exhibiting CDK12/13 dependency.

Cat. No.

A54357

CAS No.

1980822-14-7

Dalpiciclib isethionate

Synonyms: SHR-6390 isethionate

Dalpiciclib isethionate is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). By inhibiting the kinase activity of these enzymes, Dalpiciclib effectively disrupts the progression of the cell cycle from the G1 phase to the S phase, which reduces abnormal cellular proliferation. This compound is primarily utilized in cancer research, particularly in the study of breast cancer, where CDK4/6 dysregulation plays a critical role in tumor growth.

Cat. No.

A54358

CAS No.

660822-84-4

CDK-IN-10

CDK-IN-10 is a potent cyclin-dependent kinase (CDK) inhibitor that selectively blocks CDK activity. This compound has demonstrated significant antitumor effects, making it an invaluable tool for cancer research. Researchers can utilize CDK-IN-10 to investigate CDK regulation in cell cycle progression and explore its potential in therapeutic applications against various cancers.

Cat. No.

A54359

CAS No.

2457317-40-5

CDK8-IN-10

CDK8-IN-10 is a selective inhibitor of cyclin-dependent kinase 8 (CDK8), exhibiting an IC50 value of 8.25 nM. This compound is instrumental in the study of CDK8's role in cancer progression and may provide insights into therapeutic strategies targeting this kinase. Its potency and selectivity make it a valuable tool for cancer research applications.

Cat. No.

A54360

CAS No.

223784-70-1

AG-12275

AG-12275 is a selective cyclin-dependent kinase (CDK) inhibitor that targets CDK2 and CDK5. It exhibits potent inhibition of cancer cell proliferation by disrupting the cell cycle progression. This compound is valuable for investigating the roles of CDKs in cancer biology and the development of novel therapeutic strategies targeting these pathways.

Cat. No.

A54362

CAS No.

2620706-60-5

CDK9-IN-46

CDK9-IN-46 is a selective inhibitor of cyclin-dependent kinase 9 (CDK9), which plays a crucial role in transcriptional regulation. This compound demonstrates significant biological activity in reducing the phosphorylation of RNA polymerase II, thereby inhibiting gene transcription associated with cancer cell proliferation. CDK9-IN-46 is utilized in cancer research to explore therapeutic strategies targeting CDK9-dependent pathways.

Cat. No.

A54363

CAS No.

1169694-98-7

CDK4/6-IN-16

CDK4/6-IN-16 is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), exhibiting a potent activity with an IC50 of 0.013 μM for CDK4. This compound has significant implications for the study of CDK4-mediated pathologies, particularly in cancer research. Its targeted inhibition of CDK4/6 may aid in the exploration of cell cycle regulation and therapeutic strategies for cancer treatment.

Cat. No.

A54364

CAS No.

2562329-13-7

(S)-Cdc7-IN-18

(S)-Cdc7-IN-18 is a selective inhibitor of CDC7, a critical kinase involved in cell cycle regulation. By inhibiting CDC7, (S)-Cdc7-IN-18 effectively reduces the overactivation of MCM2, a key marker associated with tumor cell proliferation. This compound shows promise for research applications focused on cancer biology and therapeutic strategies aimed at countering tumorigenesis.

Cat. No.

A54365

CAS No.

330550-51-1

YY173

YY173 is a selective dual inhibitor of CDK4 and CDK6, demonstrating IC50 values of 7.7 nM and 88 nM, respectively. This compound effectively inhibits the proliferation of Jurkat cells with an IC50 of 1.46 μM. YY173 serves as a valuable tool for research in cancer biology and is suitable for the synthesis of PROTAC CDK4/6 degrader 1, facilitating studies on targeted protein degradation.

Cat. No.

A54366

CAS No.

2750638-94-7

CDK7-IN-12

CDK7-IN-12 is a selective inhibitor of cyclin-dependent kinase 7 (CDK7), which is integral to transcriptional regulation and cell cycle control. This compound demonstrates significant capacity to impede the proliferation of malignant tumors in both in vitro and in vivo studies. CDK7-IN-12 is suitable for research applications focused on cancer biology and therapeutic development.

Cat. No.

A54367

CAS No.

3054692-45-1

CDK2-IN-36

CDK2-IN-36 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), a crucial regulator of the cell cycle. This compound exhibits significant anticancer activity by disrupting CDK2-mediated phosphorylation events, thereby promoting apoptosis and inhibiting tumor cell proliferation. CDK2-IN-36 is valuable for research focused on cancer biology, cell cycle regulation, and the development of targeted cancer therapies.

Cat. No.

A54368

CAS No.

3076450-41-1

CDK12/13-IN-2

CDK12/13-IN-2 is a covalent inhibitor targeting cyclin-dependent kinases 12 and 13, with IC50 values of 15.5 nM and 12.2 nM for CDK12 and CDK13, respectively. This compound effectively inhibits the proliferation of breast cancer cells and is particularly relevant for research into triple-negative breast cancer. Its selective action provides a valuable tool for studying the effects of CDK12/13 inhibition in cancer biology.

Cat. No.

A54369

CAS No.

2498658-21-0

CDK2-IN-46

CDK2-IN-46 is a highly selective cyclin-dependent kinase 2 (CDK2) inhibitor with an IC50 value of 0.3 nM. It demonstrates a significant selectivity of over 200-fold compared to other kinases, including CDK1, CDK4, CDK6, CDK7, and CDK9. This compound is valuable for studying cell cycle regulation and has shown improved pharmacokinetic profiles in both rat and cynomolgus monkey models, making it suitable for preclinical research in cancer biology and therapeutic development.

Cat. No.

A54370

CAS No.

364735-73-9

CDK2-IN-18

CDK2-IN-18 is a potent inhibitor of cyclin-dependent kinases CDK2/E and CDK4/D1, exhibiting IC50 values of 8 nM and 46 nM, respectively. This compound effectively inhibits tumor cell proliferation, making it valuable for cancer research applications, particularly in studying cell cycle regulation and exploring therapeutic strategies targeting CDK pathways.